地诺单抗要多少钱一支？

Denosumab (trade names Prolia and Xgeva), developed by the biotechnology company Amgen, is a human monoclonal antibody and the first RANKL inhibitor approved by the FDA. It works by preventing the development of osteoclasts, cells that break down bone (bone resorption). Indicated to treat osteoporosis, therapy-induced bone loss, metastasis to bone, and giant cell tumors of bone, and to reduce the risk of fractures in cancer patients. Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle pain in the arms or legs.

On May 28, 2010, the European Commission approved denosumab for the treatment of osteoporosis and hormone suppression-related bone loss in patients with prostate cancer in postmenopausal women. On June 2, 2010, the brand name Prolia was approved by the United States (FDA) for use in postmenopausal women with the risk of osteoporosis. In November 2010, the brand name Xgeva was approved for the prevention of bone-related events in patients and the treatment of solid tumors with bone metastasis. On May 23, 2019, China’s National Medical Products Administration announced conditional approval of the import registration application for Denosumab Injection (English name: Denosumab Injection).

Desosumab injection (Angavir) can only be injected subcutaneously, not intravenously, intramuscularly or intradermally. So, how much does denosumab cost?

Price in the United States, pharmaceutical name: Prolia, pharmaceutical manufacturer: Amgen/American Amgen Biopharmaceuticals, pharmaceutical specification: 60mg/1ml tube/box, price: $1,169.98/unit: USD; pharmaceutical specification: 120mg/1.7ml bottle/box; price: $2,391.11/unit: USD. Denosumab, which is launched in Turkey, has a specification of 125mg/1ml tube/box and sells for about $3,000, which is the most cost-effective one.